drugset / Trial / NCT06614907
A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®
RandomizedParallel-groupQuadruple-blindTreatment
Summary
It is a randomized, double-blinded, parallel, single-dose, PhaseⅠcomparative study to evaluate the pharmacokinetics and safety of QL2108 to Dupixent® in healthy Chinese adult subjects. A total of 198 healthy subjects are planned to be included and randomized at a ratio of 1:1 to receive single 300mg/2.0ml QL2108 injection or Dupixent®.
Timeline
- Start
- 2024-08-31
- Primary completion
- 2024-11-15
- Completion
- 2024-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | QL2108 | Unknown | 300 mg | Subcutaneous |